Tulip Appoints Ian Rawlins as New Chief Executive Officer
Tulip Founder and former CEO
"After a decade at the helm of our journey at Tulip as CEO, I've decided the time is right to step down from an operational role and make room for a new era of leadership at Tulip," said
Rawlins' extensive knowledge of the retail customer engagement market including Clienteling, Store Systems and Point of Sale specifically, positions Tulip for success and reinforces their commitment to further develop and expand their Tulip customer engagement footprint. His expertise and insights will be instrumental in driving Tulip's growth in this critical sector.
Rawlins joined Tulip in
"I would like to thank Ali and the Board for entrusting me with the responsibility of leading Tulip into the future," said Rawlins. "As Tulip continues its impressive growth trajectory, and as we expand our operations around the world, we expect to continue to advance our position as the leading global provider of omnichannel Customer Engagement solutions including Customer Outreach, Clienteling, Appointment Management and Point of Sale. We have an impressive team of leaders and staff, an unmatched customer base who are highly engaged with us, and best in class products. It certainly is an exciting time for Tulip."
About Tulip
Tulip is the world's largest cloud-based customer engagement platform provider, with best-in-class Clienteling and Point of Sale solutions that let retailers deliver on the promise of omnichannel commerce. Leading retailers like
Media Contact
1 855-834-4587
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/tulip-appoints-ian-rawlins-as-new-chief-executive-officer-302030248.html
SOURCE Tulip
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- In HelloNation, Tax Expert Sal Julian Details Which Itemized Deductions High-Income Individuals Lose Without Knowing It
- Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European
- BOA Surpasses 2 Million Global Users and Announces Global Commerce Expansion Strategy
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share